SOURCE: Barrier Therapeutics, Inc.

August 27, 2007 07:30 ET

Barrier Therapeutics to Present at Investor Conferences During September 2007

PRINCETON, NJ--(Marketwire - August 27, 2007) - Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Dr. Geert Cauwenbergh, Chief Executive Officer, and Mr. Al Altomari, Chief Operating Officer, will present an overview of the Company's business activities and product pipeline at select investor conferences during the month of September.

The ROTH 2007 New York Conference will be held September 5-6, 2007 at the Westin Times Square Hotel in New York City. Mr. Altomari is scheduled to present at 12:30 PM ET on Wednesday, September 5, 2007.

The NewsMakers in the Biotech Industry Conference will be held Thursday, September 6, 2007 at the Millennium Broadway Hotel in New York City. Dr. Cauwenbergh is scheduled to present at 11:30 AM ET.

To listen to the audio webcasts of these presentations, please visit the Investor Relations section of Barrier Therapeutics' corporate website at: www.barriertherapeutics.com. An archive of each presentation will be available for replay for 90 days following the respectively scheduled presentations.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly-owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    EVP & CFO
    (609) 945-1202

    Lazar Partners Ltd.
    Gregory Gin
    Investor Relations
    (212) 867-1762